-
Article
Open AccessCharacterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants
The new coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic, which so far has caused over 6 million deaths in 2 years, despite new vaccines and antiviral medications. Drug repurposing, an ap...
-
Article
Open AccessB-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation
Combined antiretroviral therapy (cART) for HIV-1 dramatically slows disease progression among HIV+ individuals. Currently, lymphoma represents the main cause of death among HIV-1-infected patients. Detection of p...
-
Article
Open AccessA persistently replicating SARS-CoV-2 variant derived from an asymptomatic individual
Since the first outbreak of SARS-CoV-2, the clinical characteristics of the Coronavirus Disease 2019 (COVID-19) have been progressively changed. Data reporting a viral intra-host and inter-host evolution favou...
-
Article
Open AccessHeparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications
p17 matrix protein released by HIV+ cells interacts with leukocytes heparan sulfate proteoglycans (HSPGs), CXCR1 and CXCR2 exerting different cytokine-like activities that contribute to AIDS pathogenesis. Sinc...
-
Article
Open AccessHuman Herpesvirus 6A and 6B inhibit in vitro angiogenesis by induction of Human Leukocyte Antigen G
We have previously reported that human herpesvirus 6 (HHV-6) infection of endothelial cells (ECs) induces the loss of angiogenic properties, through the expression of HHV-6 U94, possibly associated to the rele...
-
Article
Open AccessMyroides odoratimimus urinary tract infection in an immunocompromised patient: an emerging multidrug-resistant micro-organism
Myroides spp. are common environmental organisms and they can be isolated predominantly in water, soil, food and in sewage treatment plants. In the last two decades, an increasing number of infections such as uri...
-
Article
Open AccessHIV-1 matrix protein p17 and its variants promote human triple negative breast cancer cell aggressiveness
The introduction of cART has changed the morbidity and mortality patterns affecting HIV-infected (HIV+) individuals. The risk of breast cancer in HIV+ patients has now approached the general population risk. Howe...
-
Article
Open AccessHIV-1 matrix protein p17 misfolding forms toxic amyloidogenic assemblies that induce neurocognitive disorders
Human immunodeficiency virus type-1 (HIV-1)-associated neurocognitive disorder (HAND) remains an important neurological manifestation that adversely affects a patient’s quality of life. HIV-1 matrix protein p1...
-
Article
Open AccessA single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17
Recent data highlight the presence, in HIV-1-seropositive patients with lymphoma, of p17 variants (vp17s) endowed with B-cell clonogenicity, suggesting a role of vp17s in lymphomagenesis. We investigated the m...
-
Article
Open AccessCellular aspartyl proteases promote the unconventional secretion of biologically active HIV-1 matrix protein p17
The human immune deficiency virus type 1 (HIV-1) matrix protein p17 (p17), although devoid of a signal sequence, is released by infected cells and detected in blood and in different organs and tissues even in ...
-
Article
Correction: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition
Nat. Med.; doi:10.1038/nm.4105; corrected online 16 June 2016 In the version of this article initially published online, an affiliation for Luca Schifanella was omitted and there was an error in the descriptio...
-
Article
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition
Vaccari et al. report that SIV vaccines formulated with two different adjuvants elicit distinct immune responses and effects on SIV acquisition in rhesus macaques.
-
Article
Open AccessSynthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study